# Applied Biology, Inc.: Early phase 1 study withdrawn (Chemotherapy Induced Alopecia, Chemotherapy Side Effects)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Applied Biology, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Pharmacokinetic Study of DA-020 |
| NCT ID | NCT07402330 |
| Phase | Early phase 1 |
| Status | withdrawn |
| Conditions | Chemotherapy Induced Alopecia; Chemotherapy Side Effects |
| Intervention types | drug |
| Site countries | Brazil, Italy |
| Posted | 2026-02-11 |
| Planned start | 2026-04-16 |
| Event | Withdrawn before enrolling |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07402330). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.